Despite the macroeconomic uncertainties, the biotech industry has resiliently navigated its path forward through efficient capital allocation and streamlining its core operations, from research and development to supply chain and commercial operations.
In this piece, I have evaluated the fundamentals of brilliant biotech stocks, namely, BioMarin Pharmaceutical Inc. (BMRN), Equillium, Inc. (EQ), and Organogenesis Holdings Inc. (ORGO), that have the potential for high returns coupled with groundbreaking discoveries.
